Consensus-built recommendations to improve prostate cancer outcomes: A summary of the American Cancer Society Prostate Cancer Collaborative

The incidence of prostate cancer in the United States has steadily risen since 2014, which has reversed decades of progress toward lowering the burden of prostate cancer. Mortality rates have plateaued, despite reliable screening methodology in the form of prostate-specific antigen testing, and despite a recent surge in the number of approved therapeutics for the management of primary and metastatic prostate cancer. If these trends are not addressed quickly and decisively via a multidisciplinary approach, loss of life and economic strain due to prostate cancer could precipitously increase in the coming years. To this end, the American Cancer Society (ACS) convened a collaborative of experts across the prostate cancer continuum to identify barriers to progress and generate opportunities for innovation. Through a series of consensus-building exercises and progressive refinement of themes into actionable priority areas, the collaborative identified three strategic priorities. These priorities form the backbone of an action plan to improve risk assessment and screening uptake, optimize therapeutic intervention for localized prostate cancer, and leverage the emerging arsenal of tools to more effectively manage advanced prostate cancer in the clinic. To advance this work, the ACS has launched the ACS National Prostate Cancer Roundtable to nucleate and coordinate partners from across the prostate cancer continuum to activate around these strategic priorities, and to build momentum toward improving prostate cancer outcomes for all.